FDA
-
-
-
-
-
-
-
Palisade Bio receives Japanese patent for PALI-2108 drug candidate
-
-
-
-
-
-
-
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
-
-
-
-
-
-
-
Palisade Bio Inc. (PALI) Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
-
-
-
-
-
-
-
Palisade Bio Inc. (PALI) Climbs 38% After Granted FDA Fast Track Designation for LB1148
-
-
-
-
-
-
-
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update
-
-
-
-
-
-
-
Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center
-
325,869 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

